p.s. ABBV still holds the FDA priority review-voucher purchased from UTHR for $350M in 2015 (#msg-116321586). (The voucher wasn't needed for FDA review of G/P because G/P had already been granted BTD.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”